

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

**FORM 8-K**

---

CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 9, 2010

---

**ORAMED PHARMACEUTICALS INC.**

(Exact name of registrant as specified in its charter)

Nevada  
(State or other jurisdiction  
of incorporation)

**000-50298**  
(Commission File Number)

**98-0376008**  
(IRS Employer  
Identification No.)

**Hi-Tech Park 2/5 Givat Ram**  
**PO Box 39098**  
**Jerusalem, Israel 91390**  
(Address of principal executive offices and zip code)

**Registrant's telephone number, including area code: 972-2-566-0001**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**ITEM 7.01 REGULATION FD DISCLOSURE**

On June 8, 2010, Oramed Pharmaceuticals Inc. issued a press release announcing that it was chosen to present at the 9th National Life Science & Technology Week ILSI-BIOMED Conference, Israel 2010. The presentation will be given by Nadav Kidron, Chief Executive Officer of Oramed, on Wednesday, June 16th during the BioPharma Session at 11:50 a.m. (IDT) at the David Intercontinental Hotel in Tel-Aviv, Israel.

A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

(d) Exhibits

Exhibit Number	Description
99.1	Press Release dated June 8, 2010.

---



**Exhibit Index**

Exhibit Number	Description
99.1	Press Release dated June 8, 2010.

---



**Oramed Pharmaceuticals to Present at the 9th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2010**

***Oramed to present on Wednesday, June 16<sup>th</sup> at 11:50 a.m. (IDT)***

JERUSALEM, Israel – June 8, 2010 – Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB); [www.oramed.com](http://www.oramed.com)), a developer of oral delivery systems, today announced today that it was chosen to present at the 9th National Life Science & Technology Week ILSI-BIOMED Conference, Israel 2010. The presentation will be given by Nadav Kidron, Chief Executive Officer of Oramed, on Wednesday, June 16<sup>th</sup> during the BioPharma Session at 11:50 a.m. (IDT) at the David Intercontinental Hotel in Tel-Aviv, Israel.

**Event:** National Life Science & Technology Week ILSI-BIOMED Conference, Israel 2010

**Date:** Wednesday, June 16 2010

**Time:** 11:50 a.m. (IDT), or 4:50 a.m. (EST)

For more information about the upcoming ILSI Biomed conference, please visit the following website:

<http://www2.kenes.com/biomed/Pages/Home.aspx>

**About Oramed Pharmaceuticals**

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research performed by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit <http://www.oramed.com>.

---

## **Safe Harbor Statement**

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

## **Company and Investor Relation Contacts:**

Oramed Pharmaceuticals Inc.

Tara Horn

Office: 646-240-4193

Cell: +972-54-334-4318

Email: tara@oramed.com

---